New drug for blood cancers now in five phase II clinical trials

28 julio 2015

The safety and dosing of a new drug for treating blood cancers has now been established by a group of scientists. The drug is a small molecule inhibitor that suppresses the activity of a signaling pathway believed to contribute to a variety of blood cancers’ eventual resistance to standard chemotherapy treatments.img src=»» height=»1″ width=»1″ alt=»»/